Atea Pharmaceuticals, Inc. (AVIR)
Market Cap | 272.04M |
Revenue (ttm) | n/a |
Net Income (ttm) | -163.66M |
Shares Out | 84.22M |
EPS (ttm) | -1.96 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 226,867 |
Open | 3.370 |
Previous Close | 3.370 |
Day's Range | 3.220 - 3.370 |
52-Week Range | 2.765 - 4.600 |
Beta | 0.19 |
Analysts | Sell |
Price Target | n/a |
Earnings Date | Aug 6, 2024 |
About AVIR
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license... [Read more]
Financial Performance
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/c/a/conf10-2451133.jpg)
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral thera...
![](https://cdn.snapi.dev/images/v1/v/i/press18-2443026.jpg)
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024
Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial
![](https://cdn.snapi.dev/images/v1/7/q/press13-2396644.jpg)
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral thera...
![](https://cdn.snapi.dev/images/v1/u/u/press3-2343493.jpg)
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
Enrollment Reached Over 2,200 High-Risk Patients in Bemnifosbuvir Monotherapy Cohort Results from SUNRISE-3 Expected in 2H'24 BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nas...
![](https://cdn.snapi.dev/images/v1/v/u/press19-2299494.jpg)
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Final Results Confirm 98% Sustained Virologic Response Rate at Week 4 Post-Treatment (SVR4) from Lead-in Cohort in Phase 2 HCV Study
![](https://cdn.snapi.dev/images/v1/g/t/conf19-2285507.jpg)
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral ther...
![](https://cdn.snapi.dev/images/v1/c/l/press20-2221122.jpg)
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19
A 98% Sustained Virologic Response at Week 4 (SVR4) Post-Treatment Observed in Initial Data From 52 Patients in Lead-In Cohort in Phase 2 HCV Study
![](https://cdn.snapi.dev/images/v1/w/v/conf8-2214319.jpg)
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral ther...
![](https://cdn.snapi.dev/images/v1/8/m/press11-2154146.jpg)
Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
First Clinical Data for Coadministration of Bemnifosbuvir and Ruzasvir Show Combination Was Well Tolerated in a Phase 1 Study
![](https://cdn.snapi.dev/images/v1/j/l/press20-2148036.jpg)
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
P atient enrollment continues in global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for COVID-19; first interim analysis expected 1Q24
![](https://cdn.snapi.dev/images/v1/x/f/conf1-2146360.jpg)
Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences
BOSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral ther...
![](https://cdn.snapi.dev/images/v1/e/p/conf6-2132356.jpg)
Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral ther...
![](https://cdn.snapi.dev/images/v1/g/o/conf20-2050855.jpg)
Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral the...
![](https://cdn.snapi.dev/images/v1/j/n/press10-2012967.jpg)
Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
BOSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral ther...
![](https://cdn.snapi.dev/images/v1/u/o/conf4-1998369.jpg)
Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral ther...
![](https://cdn.snapi.dev/images/v1/q/h/press11-1911796.jpg)
Atea Pharmaceuticals' Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners' Affiliate, Concentra Biosciences
Proposal Fundamentally Undervalues Atea; Not in the Best Interests of Atea or Its Shareholders Proposal Fundamentally Undervalues Atea; Not in the Best Interests of Atea or Its Shareholders
![](https://cdn.snapi.dev/images/v1/a/p/press14-1904176.jpg)
Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners' Affiliate, Concentra Biosciences
BOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Bioscien...
![](https://cdn.snapi.dev/images/v1/l/d/press2-1877786.jpg)
Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
Global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 in high-risk patients continues enrollment; execution of global geographic footprint
![](https://cdn.snapi.dev/images/v1/h/6/conf11-1863983.jpg)
Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023
BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral thera...
![](https://cdn.snapi.dev/images/v1/c/d/press5-1851665.jpg)
Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19
BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral the...
![](https://cdn.snapi.dev/images/v1/g/1/press5-1833736.jpg)
Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases
71% reduction in risk of hospitalization for mild to moderate COVID-19 outpatients treated with bemnifosbuvir versus placebo in MORNINGSKY study, regardless of vaccination status 71% reduction in risk...
![](https://cdn.snapi.dev/images/v1/v/j/press17-1795386.jpg)
New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral Research
Low risk for drug-drug interactions with bemnifosbuvir based upon results from in vitro metabolism and transporter studies
![](https://cdn.snapi.dev/images/v1/r/4/press18-1787018.jpg)
New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral Research
BOSTON, March 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting...
![](https://cdn.snapi.dev/images/v1/l/3/press18-1775392.jpg)
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 in high-risk patients continues enrollment; interim analysis expected in 2H23
![](https://cdn.snapi.dev/images/v1/a/c/press10-1767081.jpg)
Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023
Results highlight the favorable profile for bemnifosbuvir related to low risk for drug-drug interactions